文献速递MDS 与骨髓增殖性肿瘤贫血与红细胞疾病

转录组分析提示坏死性凋亡参与骨髓增生异常综合征疾病进展与预后

Transcriptomic analysis implicates necroptosis in disease progression and prognosis in myelodysplastic syndromes.
PubMed 文献 · Leukemia · 2019-11-12

该研究对55例MDS或CMML患者的64份骨髓CD34+细胞样本进行RNA-Seq,比较HMA治疗前后及与健康对照的基因表达。结果显示MLKL表达在CMML和MDS中显著上调,且与诊断时较低血红蛋白水平相关;HMA治疗后MLKL显著下降;RIPK1高表达与较短生存相关。提示坏死性凋亡参与MDS疾病表型、HMA反应及预后。

要点

  • MDS/CMML患者骨髓CD34+细胞中MLKL表达较健康对照显著上调。
  • MLKL高表达与诊断时较低血红蛋白水平相关。
  • HMA治疗后MLKL水平显著下降,尤其在不响应者中。

核心结论

  • 坏死性凋亡相关基因MLKL在MDS/CMML中表达上调并与贫血相关,RIPK1高表达与较短生存相关,提示坏死性凋亡参与疾病进展、HMA反应和预后。

研究设计与样本

  • 研究纳入55例MDS或CMML患者的64份骨髓样本,其中治疗前46份、HMA治疗后18份,对分选骨髓CD34+细胞RNA进行扩增和RNA-Seq。

主要发现

  • 与健康对照相比,MLKL表达在CMML中为2.09 log2FC(p=0.0013),在MDS中为1.89 log2FC(p=0.003),RIPK1和RIPK3无显著差异。
  • MLKL较高表达与诊断时较低血红蛋白水平相关(血红蛋白每增加1 g/dL,-0.19 log2FC,p=0.03)。
  • HMA治疗后MLKL水平显著下降(-1.06 log2FC,p=0.05),尤其在不响应者中(-2.89 log2FC,p=0.06)。
  • RIPK1较高表达与较短生存相关(HR 1.92,95%CI 1.00-3.67,p=0.049,Cox比例风险模型)。

临床怎么用

  • MLKL和RIPK1表达可能作为MDS预后及HMA反应评估的候选分子标志物。
  • RIPK1/RIPK3/MLKL轴提示为MDS潜在治疗靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis and cytopenias due to uncontrolled programmed cell death. The presence of pro-inflammatory cytokines and constitutive activation of innate immunity signals in MDS cells suggest inflammatory cell death, such as necroptosis, may be responsible for disease phenotype. We evaluated 64 bone marrow samples from 55 patients with MDS or chronic myelomonocytic leukemia (CMML) obtained prior to (n = 46) or after (n = 18) therapy with hypomethylating agents (HMAs). RNA from sorted bone marrow CD34+ cells was isolated and subject to amplification and RNA-Seq. Compared with healthy controls, expression levels of MLKL (CMML: 2.09 log2FC, p = 0.0013; MDS: 1.89 log2FC, p = 0.003), but not RIPK1 or RIPK3, were significantly upregulated. Higher expression levels of MLKL were associated with lower hemoglobin levels at diagnosis (-0.19 log2FC per 1 g/dL increase of Hgb, p = 0.03). Significant reduction in MLKL levels was observed after HMA therapy (-1.06 log2FC, p = 0.05) particularly among nonresponders (-2.89 log2FC, p = 0.06). Higher RIPK1 expression was associated with shorter survival (HR 1.92, 95% CI 1.00-3.67, p = 0.049 by Cox proportional hazards). This data provides further support for a role of necroptosis in MDS, and potentially response to HMAs and prognosis. This data also indicate that RIPK1/RIPK3/MLKL are potential therapeutic targets in MDS.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Montalban-Bravo G, Class CA, Ganan-Gomez I, et al. Transcriptomic analysis implicates necroptosis in disease progression and prognosis in myelodysplastic syndromes. Leukemia. 2019. PMID: 31719677. doi:10.1038/s41375-019-0623-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。